Skip to main content
Equibles
NAUT logo

NAUT · Nautilus Biotechnology, Inc.

Track NAUT — free

Use NAUT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NAUT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.90 -0.03 (-3.55%) At close · Aug 27
Market Cap
$119.59M
Shares
127.08M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.90 Open$0.95 Day$0.90–0.98 52W close$0.64–3.95 Avg vol 30d793K Short int3.2M · 2.5% float · 3.7d Short vol54% Last earningsJul 28, 2026 DataAug 2020–Aug 2026 Filing10-Q · Jul 28

Up next

Next earnings call
Oct 26, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 28, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −59%
      below
      Price vs 50-day avg −37%
      below
      RSI (14) 34
      neutral
      MACD trend Positive
      52-week position 8%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −12%
      trailing
      6-month return −63%
      trailing
      YTD return −54%
      this year
      Relative strength −78%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +12% holders QoQ · +29 funds added
      Insider flow Distributing
      Net -$11.8M over 90 days · 100% sells
      Short interest Rising
      2.48% of float · ▲ +38.8% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      93 holders — near 3-yr high, broad support
      Squeeze score 41
      elevated · 0–100
      Fundamentals
      Strong
      EPS growth +16%
      Y/Y
      Free cash flow $-52.0M
      Balance sheet $12.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 110%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 10.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2026
      Revenue · full year $500,000
      Operating expenses year-over-year growth · full year up to 10%
      Prior guidance period ended · from the Earnings Call filed Jun 30, 2024
      Total operating expense growth · full year 15% – 20%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −59% Bearish
      Price vs 50-day avg
      −37% Bearish
      RSI (14)
      34 Neutral
      MACD trend
      Positive Bullish
      52-week position
      8% Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      +12% holders QoQ · +29 funds added
      Insider flow Distributing
      Net -$11.8M over 90 days · 100% sells
      Short interest Rising
      2.48% of float · ▲ +38.8% MoM · 3.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      93 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 8% Range high $4
      vs 200-day avg -59% vs 50-day avg -37%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NAUT
      Nautilus Biotechnology, Inc.
      this stock
      		$119.59M -53.6% — — 2.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +4.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +25.9% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      93
      % held
      39.5%
      Net QoQ
      -4.2M sh
      Top holder
      PERCEPTIVE ADVISORS LLC
      Held Float
      View
      Held by Funds
      Fund positions
      51
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.2M
      Days to cover
      3.7d
      Change
      +881.7K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      4.6K
      Value
      $10.5K
      As of
      Jun 26, 2026
      View
      Off-Exchange
      Off-exchange %
      40.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$11.8M
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-59.0M
      EPS diluted
      $-0.47
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 28, 2026
      This year
      8
      View
      Proposed Sales
      Value
      $74.3K
      Shares
      38.3K
      Filed
      Dec 17, 2024
      View
      Exempt Offerings
      Offering
      $200.0M
      Filed
      Jun 22, 2021
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 28, 2026
      View
      Investor Relations
      Latest news
      Nautilus Biotechnology Reports Se…
      Published
      Jul 28, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NAUT +0.2% -12.2% -63.4% -7.5% -53.6%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -0.9% -16.2% -78.1% -10.7% -66.7%
      Key facts CIK 1808805 CUSIP 63909J108 13F (30d) 81 filings 80 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)